Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688067 | 0.91 | SLC22A12 (0.39) | CTSASMN1; SMN2SLC22A12CYP26A1 | |
| SCHEMBL687275 | 0.89 | SMN1; SMN2 (0.37) | CTSASMN1; SMN2SLC22A12CYP26A1 | |
| SCHEMBL688193 | 0.85 | CTSA (0.39) | CTSASMN1; SMN2MAPT | |
| SCHEMBL687048 | 0.85 | CTSA (0.41) | CTSASMN1; SMN2MAPT | |
| SCHEMBL687715 | 0.85 | CTSA (0.39) | CTSASMN1; SMN2MAPT | |
| SCHEMBL688267 | 0.84 | CTSA (0.43) | CTSASMN1; SMN2MAPTCYP26A1 | |
| SCHEMBL688172 | 0.84 | MAPT (0.41) | CTSASMN1; SMN2MAPT | |
| SCHEMBL687713 | 0.83 | CTSA (0.37) | CTSASMN1; SMN2MAPT | |
| SCHEMBL687038 | 0.83 | SMN1; SMN2 (0.43) | SMN1; SMN2MAPTCYP26A1 | |
| SCHEMBL687480 | 0.82 | CTSA (0.36) | CTSASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203766-B1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1203766-A2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2002-05-08 | — | — | EP | disclosed |